⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8

Every month we try and update this database with for pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) AdenocarcinomaNCT04097028
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Trifluridine an...
Oxaliplatin
18 Years - Roswell Park Cancer Institute
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialNCT04704661
Advanced Breast...
Advanced Colon ...
Advanced Colore...
Advanced Endome...
Advanced Gastri...
Advanced Gastro...
Advanced Malign...
Advanced Saliva...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
HER2-Positive B...
Malignant Hepat...
Metastatic Brea...
Metastatic Gast...
Metastatic Mali...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Stage III Colon...
Stage III Color...
Stage III Major...
Stage III Uteri...
Stage IIIA Colo...
Stage IIIA Colo...
Stage IIIA Uter...
Stage IIIB Colo...
Stage IIIB Colo...
Stage IIIB Uter...
Stage IIIC Colo...
Stage IIIC Colo...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Colon ...
Stage IV Colore...
Stage IV Major ...
Stage IV Uterin...
Stage IVA Colon...
Stage IVA Color...
Stage IVA Major...
Stage IVA Uteri...
Stage IVB Colon...
Stage IVB Color...
Stage IVB Major...
Stage IVB Uteri...
Stage IVC Colon...
Stage IVC Color...
Stage IVC Major...
Unresectable Co...
Unresectable Ga...
Unresectable Ma...
Ceralasertib
Trastuzumab Der...
18 Years - National Cancer Institute (NCI)
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) AdenocarcinomaNCT04097028
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Trifluridine an...
Oxaliplatin
18 Years - Roswell Park Cancer Institute
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid TumorsNCT04771520
Anatomic Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Mali...
Metastatic Mela...
Metastatic Prim...
Metastatic Sarc...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Prognostic Stag...
Prognostic Stag...
Stage IIIC Colo...
Stage IIIC Lung...
Stage IV Colore...
Stage IV Lung C...
Stage IVA Color...
Stage IVA Lung ...
Stage IVB Color...
Stage IVB Lung ...
Stage IVC Color...
Avapritinib
18 Years - M.D. Anderson Cancer Center
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyNCT03707574
Advanced Malign...
Advanced Melano...
Advanced Renal ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Stage III Color...
Stage III Lung ...
Stage III Ovari...
Stage III Prost...
Stage IIIA Colo...
Stage IIIA Lung...
Stage IIIA Ovar...
Stage IIIA Pros...
Stage IIIA1 Ova...
Stage IIIA2 Ova...
Stage IIIB Colo...
Stage IIIB Lung...
Stage IIIB Ovar...
Stage IIIB Pros...
Stage IIIC Colo...
Stage IIIC Lung...
Stage IIIC Ovar...
Stage IIIC Pros...
Stage IV Colore...
Stage IV Lung C...
Stage IV Ovaria...
Stage IV Prosta...
Stage IVA Color...
Stage IVA Lung ...
Stage IVA Ovari...
Stage IVA Prost...
Stage IVB Color...
Stage IVB Lung ...
Stage IVB Ovari...
Stage IVB Prost...
Stage IVC Color...
Biospecimen Col...
18 Years - National Cancer Institute (NCI)
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaNCT05041153
Advanced Gastri...
Advanced Gastro...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Metastatic Gast...
Metastatic Gast...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Unresectable Ga...
Unresectable Ga...
Lenvatinib
Pembrolizumab
18 Years - M.D. Anderson Cancer Center
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction CancerNCT04929392
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Esophageal Aden...
Esophageal Squa...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Carboplatin
Endoscopic Biop...
External Beam R...
Lenvatinib Mesy...
Paclitaxel
Pembrolizumab
Resection
18 Years - City of Hope Medical Center
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction CancerNCT04929392
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Esophageal Aden...
Esophageal Squa...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Carboplatin
Endoscopic Biop...
External Beam R...
Lenvatinib Mesy...
Paclitaxel
Pembrolizumab
Resection
18 Years - City of Hope Medical Center
Paclitaxel for the Treatment of Gastric or Gastroesophageal CancerNCT04220827
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Metastatic Gast...
Metastatic Gast...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Peritoneal Carc...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Paclitaxel
18 Years - M.D. Anderson Cancer Center
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal CancerNCT04522336
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Localized Gastr...
Locally Advance...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Unresectable Ga...
Docetaxel
Fluorouracil
Oxaliplatin
Pembrolizumab
Radiation Thera...
18 Years - M.D. Anderson Cancer Center
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersNCT04460937
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Distal Esophagu...
Gastric Cardia ...
Metastatic Esop...
Metastatic Esop...
Metastatic Gast...
Metastatic Mali...
Metastatic Mali...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Unresectable Es...
Unresectable Es...
Unresectable Es...
Unresectable Ga...
Adavosertib
Radiation Thera...
18 Years - National Cancer Institute (NCI)
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal CancerNCT04522336
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Localized Gastr...
Locally Advance...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Unresectable Ga...
Docetaxel
Fluorouracil
Oxaliplatin
Pembrolizumab
Radiation Thera...
18 Years - M.D. Anderson Cancer Center
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction CancerNCT03918499
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Metastatic Gast...
Metastatic Gast...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Recurrent Gastr...
Recurrent Gastr...
Cyclophosphamid...
Cytokine-based ...
Pembrolizumab
18 Years - City of Hope Medical Center
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal CancerNCT03801876
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Thoracic Esopha...
Carboplatin
Esophagectomy
Intensity-Modul...
Paclitaxel
Proton Beam Rad...
Quality-of-Life...
Questionnaire A...
FOLFOX regimen
CAPOX regimen
Docetaxel
5FU
18 Years - NRG Oncology
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric CancersNCT05296005
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Gastric Adenoca...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Capecitabine
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
Radiation Thera...
Surgical Proced...
18 Years - Ohio State University Comprehensive Cancer Center
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction CancerNCT04660760
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Metastatic Gast...
Metastatic Gast...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Paclitaxel
Quality-of-Life...
Ramucirumab
Trifluridine an...
18 Years - Academic and Community Cancer Research United
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: